Dynavax Technologies Corporation (DVAX) Earning Positive News Coverage, Study Shows
Press coverage about Dynavax Technologies Corporation (NASDAQ:DVAX) has been trending positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Dynavax Technologies Corporation earned a daily sentiment score of 0.28 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.0320281759861 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:
- Dynavax Technologies Corporation (NASDAQ:DVAX): We Made The Buy Alert At Bottom And Up 135% In Short Term (marketnewscall.com)
- Dynavax Technologies (DVAX) Presents At 24th Annual NewsMakers in the Biotech Industry – Slideshow (seekingalpha.com)
- What the Insider Data Suggests About Dynavax Technologies Corporation (DVAX) – StockNewsGazette (stocknewsgazette.com)
- Dynavax Technologies Corporation (DVAX) Upgraded to “Hold” at ValuEngine (americanbankingnews.com)
- Liam Payne Reveals Why He and Cheryl Cole Named Their Son Bear (techkenyot.com)
DVAX has been the topic of a number of recent analyst reports. Royal Bank Of Canada reiterated a “buy” rating and issued a $26.00 price objective on shares of Dynavax Technologies Corporation in a report on Friday, September 1st. Zacks Investment Research raised shares of Dynavax Technologies Corporation from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research report on Monday, July 10th. BidaskClub downgraded shares of Dynavax Technologies Corporation from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. ValuEngine raised shares of Dynavax Technologies Corporation from a “sell” rating to a “hold” rating in a research report on Thursday, September 7th. Finally, Cowen and Company reissued an “outperform” rating and issued a $30.00 target price on shares of Dynavax Technologies Corporation in a research report on Thursday, August 10th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $24.80.
Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) opened at 21.15 on Tuesday. The company’s market cap is $1.16 billion. Dynavax Technologies Corporation has a 12 month low of $3.20 and a 12 month high of $21.85. The company’s 50 day moving average is $16.02 and its 200-day moving average is $9.03.
Dynavax Technologies Corporation (NASDAQ:DVAX) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.09. Dynavax Technologies Corporation had a negative net margin of 1,323.99% and a negative return on equity of 92.09%. The company had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.15 million. During the same quarter in the prior year, the company posted ($0.75) EPS. Analysts expect that Dynavax Technologies Corporation will post ($1.58) EPS for the current fiscal year.
WARNING: This piece was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://www.dailypolitical.com/2017/09/11/dynavax-technologies-corporation-dvax-earning-positive-news-coverage-study-shows.html.
About Dynavax Technologies Corporation
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.